Comparative Pharmacology
Head-to-head clinical analysis: AZULFIDINE EN TABS versus DIPENTUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZULFIDINE EN TABS versus DIPENTUM.
AZULFIDINE EN-TABS vs DIPENTUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfasalazine is a prodrug that is cleaved by colonic bacteria to 5-aminosalicylic acid (5-ASA) and sulfapyridine. 5-ASA inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis. It also scavenges reactive oxygen species and inhibits NF-κB activation, leading to anti-inflammatory effects.
Olsalazine is a prodrug that is activated in the colon by bacterial azoreductases to release two molecules of 5-aminosalicylic acid (mesalamine), which locally inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene production, and exerts anti-inflammatory effects in the colonic mucosa.
500 mg orally twice daily, titrated to 1 g twice daily after 2 weeks for rheumatoid arthritis; 2 g daily in divided doses for ulcerative colitis.
500 mg orally twice daily, administered as two 250 mg capsules.
None Documented
None Documented
Sulfapyridine: 12-15 hours (clinical context: dosing interval typically 6-12 hours due to sulfapyridine accumulation; mesalamine: 0.6-1.5 hours, not clinically relevant)
Terminal elimination half-life of olsalazine is approximately 0.9 hours. The active metabolite, 5-ASA, has a half-life in the colon of 2-5 hours due to local retention; systemic half-life is short (0.6-1.4 hours).
Renal (50% as sulfapyridine metabolites, 33% as acetylsulfapyridine, 15% as sulfapyridine glucuronide, 2% as unchanged sulfapyridine; 15-20% as mesalamine metabolites), biliary/fecal (minimal, primarily mesalamine excreted in feces)
Primarily renal (80%), with fecal/biliary excretion up to 20% as olsalazine and metabolites (mainly 5-ASA).
Category C
Category C
Aminosalicylate
Aminosalicylate